Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United ...

In a spacious therapy room at Bethany Children's Health Center, young patients move freely without fear of falling, supported ...

indicated for the treatment of HIV-1 infection in pediatric patients aged at least 3 months and weighing at least 6 kg. Abacavir, dolutegravir and lamivudine tablets for oral suspension ...

It noted that genuine Artemether/Lumefantrine tablets or suspension was a combination ... “Also, poor-quality pediatric formulations or medicines in general have the potential of causing ...

The CHMP also recommended a pediatric marketing authorization for Tuzulby, a modified-release chewable tablet for ADHD symptoms. Tuzulby’s active ingredient, methylphenidate hydrochloride ...

It's a pioneering way to get patients to where they need to be, whether that's a hospital emergency room, an urgent care center, a laboratory for blood work, an imaging center for an x-ray, or a ...

With each student in Japan receiving a tablet, digital devices nowadays are indispensable. At the same time, children's ...

Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...

The stock price of Zydus Lifesciences surged over 5 per cent in the Tuesday trading session after the drugmaker’s wholly ...

Once abandoned, these youth can face time in shelters or eventually age out of foster care, advocates and providers say.

Tebapivat is under clinical development by Agios Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome.